Pharming Group (PHAR)
(Delayed Data from NSDQ)
$9.80 USD
-0.65 (-6.22%)
Updated Apr 26, 2024 02:34 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHAR 9.80 -0.65(-6.22%)
Will PHAR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PHAR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAR
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?
PHAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
Other News for PHAR
Pharming Group’s Strategic Financial Maneuver
Pharos Energy Announces AGM and Annual Report
Pharos Energy Announces AGM and Year-end Report
Pharming Group Lauded for Rare Disease Treatment
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards